News in Brief

AudioCure Pharma GmbH, a pharmaceutical company based in Berlin, Germany, announced today that the first healthy volunteers have been included into the Phase I trial with the first-in-class molecule AC102. Main primary endpoints of the open-label study are safety and tolerability of AC102-suspension after injection into the middle ear.

The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL). Comprehensive...

The 3rd of March is World Hearing Day. On the occasion the World Health Organization (WHO) issued its first World Report on Hearing. Hearing disorders are known to be a global problem. The WHO however warns that by 2050 nearly 2.5 billion people will be living with some degree of hearing loss unless action is taken. In other words: In less than 30 years 1 in 4 people worldwide could be affected.

AudioCure Pharma GmbH, a pharmaceutical company based in Berlin, Germany, announced today that the first healthy volunteers have been included into the Phase I trial with the first-in-class molecule AC102. Main primary endpoints of the open-label study are safety and tolerability of AC102-suspension after injection into the middle ear.

AudioCure has made exciting progress in its preclinical program by extending both its indication and compound pipelines in recent months. We are very pleased to announce that we have therefore extended our scientific team to continue pushing our preclinical...

The EMA’s Committee for Orphan Medicinal Products has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may be of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural...

We are very happy to announce that we have expanded our team with further experts for formal preclinical and clinical development to propel our way into the clinical stage …

Reimar Schlingensiepen succeeds Prof. Hans Rommelspacher, the founder of AudioCure, as CEO. Prof. Rommelspacher will continue as CSO.

It is with great pleasure that we announce the relaunch of our corporate brand and website. The brand design has been refined and updated to reflect AudioCure’s innovative and forward-thinking outlook. Meanwhile, we hope that with its clear structure, easy navigation...

AudioCure Pharma GmbH secures funding of about EUR 9 Million for the further development of their lead candidate, AC102, in hearing loss. Austrian company MED-EL Elektromedizinische Geräte GmbH (MED-EL), Innsbruck, the technology leader in implantable hearing...